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Magnetic resonance spectroscopy in focal brain lesions
Muhammad Shahbaz Alam, Zafar Sajjad, Saima Hafeez, Waseem Akhter
Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan.

Abstract
Objective: To describe the spectrum of Magnetic Resonance spectroscopy in focal brain lesions and determine
its diagnostic accuracy using histopathology as gold standard in differentiating neoplastic and non-neoplastic
focal brain lesions.
Methods: The study was conducted in Department of Radiology, Aga Khan University Hospital, Karachi from
Dec 2006 till Jan 2009. Fifty three patients found to have focal brain lesions on magnetic resonance imaging
(MRI) were included in the study. Magnetic Resonance spectroscopy (MRS) was performed in these focal
lesions. These lesions were deemed neoplastic and non-neoplastic on MR Spectrum findings. Correlation of all
these findings was done with histopathology obtained in all these patients. Sensitivity, specificity, positive,
negative predictive values and diagnostic accuracy of MR Spectroscopy was calculated. Percentage agreement
between spectroscopy and histopathology was also calculated using kappa statistics.
Results: Increase Choline/creatine and Choline/NAA ratio noted in neoplastic lesions compared to nonneoplastic lesion with significant p-value. MR Spectroscopy has a sensitivity of 93.02%, specificity of 70%,
positive predictive value of 93.02%, negative predictive value of 70% and diagnostic accuracy of 88.67 % in
differentiating neoplastic and non-neoplastic brain lesions. Kappa statistics shows a good agreement between
MR Spectroscopy and histopathology (k= 0.630).
Conclusion: Magnetic Resonance spectroscopy (MRS) is non-invasive sensitive, however, relatively nonspecific modality in differentiating neoplastic and non-neoplastic brain lesions. This modality should be
considered as an adjunct to conventional imaging rather than replacement for histopathological evaluation.
Keywords: Magnetic Resonance Spectroscopy, Focal brain lesions, Neoplastic, Non-neoplastic (JPMA 61:540; 2011).

Introduction
When a patient comes for the evaluation of a focal
brain lesion, it is often difficult to differentiate between
tumoral and non-tumoral brain lesions and frequently creates
a dilemma for physicians and surgeons for further
management.1 Routine CT and MR scanning are the first line
imaging modalities; however, it does not always provide
more precise details and characterization of the lesions
whether it is benign or malignant. Conventional imaging
techniques do not provide exact information about
vascularity, cellularity and metabolism of the mass lesion.1,2
Further work-up is needed if the results deem benign or
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equivocal on imaging. In contrary to that, more aggressive
approach like surgery or biopsy is needed for malignant
lesions.1-4 However, in many cases, true demarcation
between tumoral and non-tumoral lesion is complex and even
not possible. Thus lots of patients go through unwanted
invasive procedures to rule out malignant lesions.
Magnetic
Resonance
Spectroscopy
(MR
Spectroscopy) is one of the tools used to determine the
molecular structures of compounds or to detect the compound
presence.4 MR Spectroscopy provides metabolic information
from living brain. The major brain metabolites detected are
choline, creatine, N-acetyl aspartate (NAA), lactate, myo-
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inositol, glutamine, glutamate, lipids and the amino acids
leucine and alanine.5,6 Brain lesions show abnormal values of
these metabolites as compared to normal tissue.
MR Spectroscopy is a potential tool for differentiating
neoplastic from non-neoplastic brain lesions.7 Several studies
have been done worldwide on role of MR Spectroscopy in
characterizing and grading neoplastic lesions and
differentiating them from focal non-neoplastic lesions like
infarct, haemorrhage and infectious lesions. To our
knowledge, no data has been published locally from our part
of world, therefore, purpose of this study is to describe the role
of MR Spectroscopy in focal brain lesions and determine its
diagnostic accuracy using histopathology as the gold standard.

Patients and Methods
From 5th December 2006 till 12 January 2009, a total
of 53 patients with focal brain lesion were referred to the
department of Radiology, Aga Khan University Hospital,
Karachi, for MR Spectroscopy examination. Most common
clinical presentation was upper and lower limb weakness
(28%) followed by headache (24%). There were 40 (75.5%)
male patients while 13 (24.5%) were females. Overall mean
age was 40 ± 18 years with a range from 4 to 76 years. For
males, age ranged between 6 and 76 years with mean age of
41 ± 16 years while in females it ranged from 4 to 67 years
with a mean age of 34 ± 22 years.
All the patients found to have focal brain lesions on
conventional MRI sequences were included in the study. MR
Spectroscopy was performed in all these patients after
informed consent. Those patients who do not have
histopathological analysis, were lost to follow-up or lesion
was not suitable for spectroscopy on the basis of location,
were excluded from the study.
All MR Spectroscopy was performed through single
voxel technique. Initially, post contrast conventional MR
imaging was done to localize the lesion and then voxel was
placed on volume of interest. After water suppression, a
point-resolved spectroscopy (PRESS) technique was used for
localization and the studies were obtained with parameters
including TE and TR of 135 and 1500 respectively. All the
images were interpreted by consultant radiologists having
experience in MR spectroscopy. Reporting was done on
console as well as hard copies.
On the basis of Magnetic Resonance spectroscopy
findings, lesions were categorized into neoplastic and nonneoplastic lesions. The spectra were analyzed for the signal
intensity of NAA, choline, and creatine and for the presence
of lipid and lactate peak. Ratios were manually calculated for
Cho/Cr, and Cho/NAA ratio. NAA is a marker of neuronal
integrity and peaks at 2.02 ppm. Choline is an indicator of
cell turnover and peaks at 3.22 ppm. Similarly, creatine is
Vol. 61, No. 6, June 2011

involved in cell metabolism and peaks at 3 ppm. Lipid and
lactate peak are normally absent in brain tissue and when
present peak at 1.33 ppm and may overlap each other.
Neoplastic lesions have elevated choline and reduced NAA
peaks on MR spectrum with increase choline /creatine and
choline/ NAA ratios. Reduced Cho, Cr and NAA peaks on
MR spectrum are suggestive of non-neoplastic lesions.
Cho/creatine and choline/NAA ratio are usually not altered in
non-neoplastic lesions. Lipid and lactate peak can be seen in
high grade tumours and also in infectious lesions. Lesion was
also evaluated on conventional MR sequences before making
the final MRS diagnosis. Final diagnosis was made on
histopathology.
Data was entered using Statistical Package of Social
Sciences (SPSS) programme version 16.0. Percent agreement
between spectroscopy and histopathology for focal brain
lesion in differentiating from neoplastic and non-neoplastic
lesion was calculated by using kappa statistic. P value less
than 0.05 was considered as significant. Sensitivity,
Specificity, positive, negative predictive value and accuracy
of MR Spectroscopy was calculated. Comparisons of mean
value of neoplastic and non-neoplastic lesions were done by
using t-test.

Results
Out of the 53 cases, 43 were read by magnetic
resonance spectroscopy as neoplastic lesion. On later
histopathological examination, 43 (81%) of the total 53
cases had neoplastic lesion while 10 (19%) were diagnosed
as non-neoplastic lesions. Among the male patients, the
neoplastic lesions were seen in 75% (30/40) cases while in
females it was 100% (13/13). The neoplastic lesions

Figure-1: MR Spectrum of homogenously enhancing mass in left basal ganglia
showing increase Cho and reduced NAA peak. Histopathology showed NonHodgkin's Lymphoma.
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diagnostic accuracy of 88.67%.
After calculating the percent agreement by chance
alone, kappa statistics was applied which showed a good
agreement between MR Spectroscopy and histopathology for
differentiating neoplastic and non-neoplastic lesions
[k=0.630, p- value, <0.001].

Discussion

Figure-2: MR Spectrum of Abscess cavity in the right periventricular region
showing reduced Cho, Cr and NAA peak; however, large lactate peak was noted.

included various grades of Astrocytoma (n = 24), metastasis
(n= 7), non-Hodgkin's lymphoma (n =3), anaplastic
ependymoma (n = 2), oligodendroglioma (n =3), and
neuroectodermal tumours (n = 4).
The histologically non-neoplastic lesions included
granulomatous infections (n = 5), chronic reactive tissue (n =
3), bacterial abscess (n=1) and fungal infection (n=1).
Increase Cho/Cr (5.38 ± 6.10) and Cho/NAA (11.33 ±
16.3) ratio were observed in neoplastic lesions as compared
to non-neoplastic lesions (Cho/Cr = 2.85 ± 2.47) (Cho/NAA
= 3.15 ± 2.67) in this study with significant p-value of 0.005.
Similarly, significant increased Choline value (2.51 ± 1.8)
mmol/l was noted in neoplastic lesions compared to (1.41 ±
0.73) mmol/l in non-neoplastic lesions with p-value of 0.000.
Mean NAA value in neoplastic lesion was (0.45 ± 0.35)
mmol/l compared to (0.60 ± 0.29) mmol/l in non-neoplastic
lesions with p-value of 0.000. The mean Cr value in
neoplastic lesion was (0.73 ± 0.64) mmol/l compared to (0.65
± 0.44) mmol/l in non-neoplastic lesions with significant pvalue of 0.001.
Spectrum was also observed for presence or absence
of lactate/lipid peak. Regarding lactate and lipid peak,
lipid/lactate peak were observed in 26 spectrums. Of these 18
(41.86%) were noted in 43 neoplastic lesions and 8 (80%) in
10 non-neoplastic lesions.
Thus there were 40 true positive, 3 false positive, 7
true negative and 3 false negative results reported on MRS
based assessment of likely neoplastic brain lesions.
Based on these findings, MR Spectroscopy has a
sensitivity of 93.02%, specificity of 70%, positive predictive
value of 93.02%, and negative predictive value of 70% and
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CT and MRI are sensitive tools for categorizing space
occupying brain lesion, but they cannot really distinguish
between neoplastic and non-neoplastic brain lesions. Through
magnetic resonance spectroscopy, chemical structure of the
lesion can be determined. MR Spectroscopy can help in
differentiating neoplastic from non-neoplastic lesions.1-7 MR
Spectrum was obtained from the focal brain lesion after
placing appropriate voxel.8 Lesions can be categorized into
neoplastic and non-neoplastic on the basis of certain criteria
including Cho/Cr and Cho/ NAA ratio and choline and NAA
peak on MR Spectrum.9,10 Lipid and lactate peak are also
assessed on the spectrum.
Previous studies evaluating a heterogeneous group of
patients, some with known prior tumour, some with unknown
new masses, showed variable diagnostic test characteristics
for MRS with sensitivities ranging from 79% to 100% and
specificity ranges from 74% to 100%. The positive predictive
values ranged from 92% to 100%, while the negative
predictive values ranged from 60% to 100%.1,10-13 These
figures are in close agreement with our study in which MRS
showed a sensitivity of 93% and a specificity of 70%.
Positive predictive value was 93% and negative predictive
value was 70%. Diagnostic accuracy was 88%.
Neoplastic brain lesions usually show an increased
choline peak, reduced NAA and the presence of lipid or
lactate peak which are absent under normal circumstances.
Increased Choline values (2.51 ± 1.8) mmol/l noted in
neoplastic lesion compared to (1.41 ± 0.73) mmol/l in nonneoplastic lesions in this study with significant p-value which
is in concordance with international literature.1,7,14 Similarly
increased Cho/Cr (5.38 ± 6.10) and Cho/NAA (11.33 ± 16.3)
ratio were observed in neoplastic lesions as compared to nonneoplastic lesions (Cho/Cr = 2.85 ± 2.47) (Cho/NAA = 3.15
± 2.67) in this study with significant p-value of 0.005. Kumar
et al15 reported high Cho/Cr ratio in high grade gliomas (3.50
± 1.00) and meningioma (6.65 ± 2.83). Stadlbauer et al16
found increased mean Choline concentration of 2.86 ± 0.98
mmol/l compared to control group 1.91 ± 0.34 mmol/l in
cases of gliomas. Tien et al17 showed increased Cho/Cr ratio
(2.7 ± 1.3) in high grade gliomas.
Regarding non-neoplastic lesions, relative low value
of Cho (1.41 ± 0.73) mmol/l are observed along with decrease
Cho/Cr (2.85 ± 2.47) and Cho/NAA (3.15 ± 2.67) ratio.
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Kumar et al15 described mean Cho/Cr ratio of 1.34 ± 0.18 in
tubercular lesions.
Lipid/lactate are relatively non-specific in
differentiating neoplastic from non-neoplastic lesions as
same can be found in both as described in results of this study
and previous literature. Gupta R et al18 described the presence
of lipid/lactate peak in both pyogenic and tuberculous
abscesses, however, more frequently in tuberculous lesions.
Kumar et al15 also described presence of lipid/lactate peak
both in gliomas as well as tuberculous lesions. Kim et al19
also reported similar results.
Although high accuracy (88%) was noted in our
results, there were 3 false positive and 3 false negative results.
This could be due to various factors; one of them is voxel
position. Voxel position is critical to the accuracy of MR
spectroscopy findings.20 Placement of a voxel at the leading
edge of an enhancing lesion appears to increase the likelihood
of including viable proliferating tumour in the spectroscopy
volume and to decrease the chance of including microscopic
foci of necrosis. Another possible factor is due to lesions
present in the periphery close to the bones or base of the skull
are most likely to have increased noise, thus hindering
accuracy of the spectrum obtained from the lesion.
Our study had few limitations. It is a single centre
study and the sample size was small especially for nonneoplastic lesions. The reason for this may be that most
lesions deemed non-neoplastic were not biopsied.
Spectroscopy was performed through single voxel technique
rather than multi-voxel. Inter-observer agreement for
interpretation of spectroscopy images was not calculated.
Increase spectroscopy costs as well as increase scanning time
are also the potential disadvantages.

Conclusion
MR Spectroscopy is a highly sensitive tool; however,
its specificity is relatively low in differentiating neoplastic
from non-neoplastic lesions. Overall in our study the
sensitivity, specificity, PPV, NPV and diagnostic accuracy
was 93%, 70%, 93%, 70% and 89% respectively. Relatively,
low specificity and negative predictive values makes MRS
inadequate as the definitive diagnostic tool; however, it can
be used as an additional tool prior to biopsy which is highly
specific and sensitive. This modality should be considered as
an adjunct to conventional imaging rather than replacement
for histopathological evaluation.
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